A Cross-Country Comparison of Rivaroxaban Spontaneous Adverse Event Reports and Concomitant Medicine Use with the Potential to Increase the Risk of Harm
- 458 Downloads
Concerns with the safety profiles of the newer anticoagulants have been raised because of differences in treatment populations between pre-marketing studies (randomized controlled trials) and clinical practice. Little is known about the potential safety issues and the reporting in spontaneous adverse event databases associated with rivaroxaban.
To analyse spontaneous adverse event reports associated with the oral anticoagulant rivaroxaban from Australia, Canada and the USA; and to examine concomitant medicine use that may increase the risk of adverse events.
Spontaneous adverse event report databases from Australia, Canada and the USA were examined for all reports of adverse events associated with rivaroxaban and concomitant medicines from 1 August 2005 to 31 March 2013. Disproportionality analysis (the proportional reporting ratio [PRR] and reporting odds ratio [ROR]) was conducted for quantitative detection of signals, using the US database.
There were 244 spontaneous adverse event reports associated with rivaroxaban from Australia, 536 from Canada and 1,638 from the USA. Reporting of haemorrhage (any type) was common, ranging from 30.7 % for Australia to 37.5 % for Canada. Gastrointestinal haemorrhage was the most commonly reported haemorrhage, accounting for 13.9 % of Australian, 16.4 % of Canadian and 11.1 % of US adverse event reports. Positive signals were confirmed in the US data (haemorrhage [any type] PRR 11.93, χ 2 4,414.78 and ROR 13.41, 95 % confidence interval [CI] 12.13–14.81; gastrointestinal haemorrhage PRR 12.52, χ 2 2,018.48 and ROR 13.15, 95 % CI 11.36–15.21). Reporting of concomitant use of medicines with the potential to increase bleeding risk ranged from 63.7 % in Australia to 89.2 % in Canada.
A large proportion of adverse event reports for rivaroxaban were associated with use of concomitant medicines, which may have increased the risk of adverse events—in particular, haemorrhage. Increased awareness of a patient’s comorbidity and associated medicine use is needed when rivaroxaban is used in clinical practice.
KeywordsDabigatran Rivaroxaban Dronedarone Reporting Odds Ratio System Organ Class
This work was supported by an Australian Government National Health and Medical Research Council Centre of Research Excellence in Post-Marketing Surveillance of Medicines and Medical Devices grant (no. APP1040938).
Conflict of interest
Cameron J. McDonald, Lisa M. Kalisch Ellett, John D. Barratt and Gillian E. Caughey have no conflicts of interest that are directly relevant to the content of this study.
- 1.Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498.Google Scholar
- 3.Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365:883–91.PubMedCrossRefGoogle Scholar
- 9.Australian Therapeutic Goods Administration. Database of Adverse Event Notifications (DAEN). 2013. http://www.tga.gov.au/safety/daen.htm. Accessed 2013 Jun 25.
- 10.Health Canada. Canada Vigilance Adverse Reaction Online Database. 2013. http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php. Accessed 2013 Jul 1.
- 11.US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). 2013. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed 2013 Jun 25.
- 12.Therapeutic Guidelines Limited. Therapeutic guidelines: cardiovascular. Version 6. 2012. http://www.Tg.Org.Au/. Accessed 2013 Jul 25.
- 13.Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2013.Google Scholar
- 16.McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. Epub 2014 May 20. doi: 10.1002/pds.3648.
- 17.Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707–17.Google Scholar
- 23.Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation: quality and cost implications. Am J Med. Epub 2014 May 20. doi: 10.1016/j.amjmed.2014.05.013.